Erik Mascher
Chief Tech/Sci/R&D Officer bij KARESSA PHARMA HOLDING AB (PUBL)
Profiel
Erik Mascher is currently the Chief Technology Officer at Karessa Pharma Holding AB since 2015.
Prior to this, he worked as a Director at MAKK Consulting AB, Vice President-Process Development & Production at Resistentia Pharmaceuticals AB, and Section Manager & Senior Scientist at General Electric Healthcare España SA. Dr. Mascher holds a doctorate degree from the University of Uppsala.
Actieve functies van Erik Mascher
Bedrijven | Functie | Begin |
---|---|---|
KARESSA PHARMA HOLDING AB (PUBL) | Chief Tech/Sci/R&D Officer | 01-01-2015 |
Eerdere bekende functies van Erik Mascher
Bedrijven | Functie | Einde |
---|---|---|
MAKK Consulting AB | Director/Board Member | - |
General Electric Healthcare España SA
General Electric Healthcare España SA Wholesale DistributorsDistribution Services Part of General Electric Co., General Electric Healthcare España SA is a private company based in Alcobendas, Spain. The Spanish company specializes in providing innovative solutions to customers across different industries to accelerate the electrification and decarbonization of the world. The company's GE digital software is an essential tool that helps customers achieve their goals. Recently, the company has introduced six GE innovations that are about to change everything. | Corporate Officer/Principal | - |
Resistentia Pharmaceuticals AB
Resistentia Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Resistentia Pharmaceutical's business strategy is to develop and commercialize immunotherapy as a second generation therapy to monoclonal antibodies for the treatment of chronic diseases. Resistentia’s most advanced program is an immunotherapy against allergy/asthma – a growing health problem with a large unmet medical need. In contrast to existing therapies, which are largely symptomatic, Resistentia’s novel immunotherapeutic approach targets the cause of the allergic reactions, rather than the symptoms. In addition, Resistentia is developing an immunotherapy for the treatment of rheumatoid arthritis. The project is currently in discovery phase. | Corporate Officer/Principal | - |
Opleiding van Erik Mascher
University of Uppsala | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 4 |
---|---|
Resistentia Pharmaceuticals AB
Resistentia Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Resistentia Pharmaceutical's business strategy is to develop and commercialize immunotherapy as a second generation therapy to monoclonal antibodies for the treatment of chronic diseases. Resistentia’s most advanced program is an immunotherapy against allergy/asthma – a growing health problem with a large unmet medical need. In contrast to existing therapies, which are largely symptomatic, Resistentia’s novel immunotherapeutic approach targets the cause of the allergic reactions, rather than the symptoms. In addition, Resistentia is developing an immunotherapy for the treatment of rheumatoid arthritis. The project is currently in discovery phase. | Health Technology |
General Electric Healthcare España SA
General Electric Healthcare España SA Wholesale DistributorsDistribution Services Part of General Electric Co., General Electric Healthcare España SA is a private company based in Alcobendas, Spain. The Spanish company specializes in providing innovative solutions to customers across different industries to accelerate the electrification and decarbonization of the world. The company's GE digital software is an essential tool that helps customers achieve their goals. Recently, the company has introduced six GE innovations that are about to change everything. | Distribution Services |
Karessa Pharma Holding AB
Karessa Pharma Holding AB Pharmaceuticals: MajorHealth Technology Karessa Pharma Holding AB engages in the development and commercialization of products in the therapeutic area of erectile dysfunction. Its patented drug is an alignate-based polymer film that is applied to the oral mucosa, which then rapidly delivered out into the bloodstream. The company was founded by Fredrik Hubinette on September 11, 2013 and is headquartered in Taby, Sweden. | Health Technology |
MAKK Consulting AB |